DoseMe has created a software platform that uses patient data and laboratory results to estimate a person?s metabolism to accurately provide the best possible level of drug dosage. Patient benefits of DoseMe include the increase of childhood leukaemia survival by 10 percent, the halving of chemotherapy side effects, increase in patients in therapeutic range from 35 percent to 90 percent and overall reduction in mortality rates by 50 percent. While patient benefits are clear, the cost savings are also impressive. DoseMe looks to save more than US$2,500 per patient and reduce hospital stay length by up to 16 days. www.doseme.com.au